Your partner in Engineered Affinity
Our Mission:
Our Vision:
Our Offering:
Cutting-Edge Technologies:
Our revolutionary synthetic short RNA binders ensure ultra-high specificity and sensitivity in binding to targeted proteins/peptides. Our first diagnostic products run on standard instrumentation, using minimal sample volumes, saving time and resources. Our novel approaches enable unrivaled target specificity and sensitivity, outperforming conventional methods and accelerating product development.
SCIENCE
The importance of RNA in biological processes is increasingly recognized in the scientific community. The 2024 Nobel Prize in Medicine was awarded for the discovery of miRNA and its role in post-transcriptional gene regulation.
While endogenous miRNA and their exogenous cousins siRNA are part of the regulatory mechanism of protein biosynthesis, our synthetic short RNA takes a different approach. These synthetic short constructs are engineered to bind to specific regions of targeted proteins, opening up new possibilities for clinical diagnostics applications and beyond.
At Nemdx, we’re not just following nature’s lead – we’re charting new territories in RNA science. Join us as we unlock the full potential of RNA-protein interactions and pave the way for the next generation of medical and biotechnological breakthroughs.
Synthetic short RNA
- Perfect protein binding
- Artificial construct
- Engineered affinity
- Synthetic origin
- Hairpin loop
- 14 - 90+ mers in size
miRNA
- No protein binding
- Natural regulator
- Affinity to plants/animals
- Endogenous
- Single stranded
- 19 - 25 mers in size
siRNA
- No protein binding
- Natural silencer
- Not in mammals
- Exogenous
- Double stranded
- 21- 23 mers in size
Read More About
A Collective of Visionary Innovators and Tech Experts Committed to Pioneering Breakthroughs in RNA Science and Transforming the Future of Biotechnology.
Nemdx Assays:
A new standard for Researchers and Labs
- Neurodegenerative diseases
- Cancer research
- Infectious diseases
- Pharmaceutical studies
Your Partner in
engineered affinity:
- High accuracy and precision in detecting disease markers or biomolecules
- Detection of low concentrations of biomarkers with minimal false positives or false negatives
- Quick turnaround times enable researchers to monitor patient responses to therapies and make adjustments as needed
- Low sample volume requirements to allow non-invasive or less invasive testing
Uncover the Innovative Processes Driving Breakthroughs in RNA Technology, From In-Silico Design to Clinical Trials, Shaping the Future of Precision Medicine.
Nemdx's Recent
News & Other Resources
NEMDX
Contact Us
NEMDX
Locations
- Headquarters: Boston, MA, USA
- R&D Lab: Discovery Park, Sandwich, UK
- Commercial Lab: Framingham, MA, USA